Evaluating the Safety and Efficacy of a Biologic Drug for Asthma Management

This chapter discusses the safety and tolerability of a new subcutaneous biologic drug for asthma treatment, based on data from the Navigator trial. It highlights the drug's effectiveness in reducing asthma exacerbations while revealing that most reported adverse effects were mild and more common in the placebo group.